{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:06Z","timestamp":1786988046593,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejim.2022.04.020","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T09:13:56Z","timestamp":1651828436000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond"],"prefix":"10.1016","volume":"102","author":[{"given":"Cristina","family":"Morelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8841-5902","authenticated-orcid":false,"given":"Gessica","family":"Ingrasciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-9266","authenticated-orcid":false,"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejim.2022.04.020_bib0001","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvv023","article-title":"Targets for therapy in sarcomeric cardiomyopathies","volume":"105","author":"Tardiff","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.ejim.2022.04.020_bib0002","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0959-440X(97)80033-4","article-title":"Architecture and function in the muscle sarcomere","volume":"7","author":"Squire","year":"1997","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.ejim.2022.04.020_bib0003","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","article-title":"Molecular genetic basis of hypertrophic cardiomyopathy","author":"Marian","year":"2021","journal-title":"Circ. Res."},{"issue":"17","key":"10.1016\/j.ejim.2022.04.020_bib0004","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","article-title":"Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy","volume":"107","author":"Richard","year":"2003","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ejim.2022.04.020_bib0005","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJM199912023412302","article-title":"Missense mutations in the rod domain of the lamin A\/C gene as causes of dilated cardiomyopathy and conduction-system disease","volume":"341","author":"Fatkin","year":"1999","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejim.2022.04.020_bib0006","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa1110186","article-title":"Truncations of titin causing dilated cardiomyopathy","volume":"366","author":"Herman","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2022.04.020_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010226","article-title":"Direct sarcomere modulators are promising new treatments for cardiomyopathies","volume":"21","author":"Tsukamoto","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"35","key":"10.1016\/j.ejim.2022.04.020_bib0008","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.ejim.2022.04.020_bib0009","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of Aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.ejim.2022.04.020_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00176-5","article-title":"Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil","volume":"8","author":"Planelles-Herrero","year":"2017","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.ejim.2022.04.020_bib0011","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small molecules in development for the treatment of spinal muscular atrophy","volume":"59","author":"Calder","year":"2016","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.ejim.2022.04.020_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0096921","article-title":"Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model","volume":"9","author":"Hwee","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.ejim.2022.04.020_bib0013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2618","article-title":"Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases","volume":"18","author":"Russell","year":"2012","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejim.2022.04.020_bib0014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1021\/acsmedchemlett.7b00546","article-title":"Discovery of tirasemtiv, the first direct fast skeletal muscle troponin activator","volume":"9","author":"Collibee","year":"2018","journal-title":"ACS Med Chem Lett"},{"issue":"7\u20138","key":"10.1016\/j.ejim.2022.04.020_bib0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/21678421.2019.1612922","article-title":"A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis","volume":"20","author":"Shefner","year":"2019","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"20","key":"10.1016\/j.ejim.2022.04.020_bib0016","doi-asserted-by":"crossref","first-page":"14930","DOI":"10.1021\/acs.jmedchem.1c01067","article-title":"Discovery of reldesemtiv, a fast skeletal muscle troponin activator for the treatment of impaired muscle function","volume":"64","author":"Collibee","year":"2021","journal-title":"J Med Chem"},{"issue":"3\u20134","key":"10.1016\/j.ejim.2022.04.020_bib0017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/21678421.2020.1822410","article-title":"A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS","volume":"22","author":"Shefner","year":"2021","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"10.1016\/j.ejim.2022.04.020_bib0018","article-title":"Cytokinetics announces start of COURAGE-ALS, a phase 3 clinical trial of Reldesemtiv in patients with amyotrophic lateral sclerosis| cytokinetics","author":"Weiser","year":"2022","journal-title":"Cytokinetics"},{"key":"10.1016\/j.ejim.2022.04.020_bib0019","doi-asserted-by":"crossref","unstructured":"Ommen S.R., Mital S., Burke M.A., et\u00a0al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Vol 142.; 2020. doi:10.1161\/cir.0000000000000937.","DOI":"10.1161\/CIR.0000000000000937"},{"issue":"2","key":"10.1016\/j.ejim.2022.04.020_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/bio.057646","article-title":"Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics","volume":"10","author":"Schmid","year":"2021","journal-title":"Biol Open"},{"issue":"1","key":"10.1016\/j.ejim.2022.04.020_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-36706-4","article-title":"Proposed mechanism for the length dependence of the force developed in maximally activated muscles","volume":"9","author":"Marcucci","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ejim.2022.04.020_bib0022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11897-021-00523-0","article-title":"Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives","volume":"18","author":"Zampieri","year":"2021","journal-title":"Curr Heart Fail Rep"},{"issue":"4","key":"10.1016\/j.ejim.2022.04.020_bib0023","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12265-009-9131-8","article-title":"Mechanical and energetic consequences of HCM-causing mutations","volume":"2","author":"Ferrantini","year":"2009","journal-title":"J Cardiovasc Transl Res"},{"issue":"5","key":"10.1016\/j.ejim.2022.04.020_bib0024","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","article-title":"Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"471","author":"Spudich","year":"2019","journal-title":"Pflugers Arch Eur J Physiol"},{"issue":"10253","key":"10.1016\/j.ejim.2022.04.020_bib0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2022.04.020_bib0026","series-title":"Cytokinetics announce results from redwood-hcm and galactic-hf presented in late breaking clinical trial session at the hfsa","author":"Weiser","year":"2022"},{"issue":"40","key":"10.1016\/j.ejim.2022.04.020_bib0027","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ejim.2022.04.020_bib0028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ejhf.1715","article-title":"Hypertrophic cardiomyopathy: the future of treatment","volume":"22","author":"Tuohy","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2022.04.020_bib0029","doi-asserted-by":"crossref","unstructured":"Green E.M., Wakimoto H., Anderson R.L., et\u00a0al. Heart disease: a small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science (80-). 2016;351(6273):617\u201321. doi:10.1126\/science.aad3456.","DOI":"10.1126\/science.aad3456"},{"issue":"12","key":"10.1016\/j.ejim.2022.04.020_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0168407","article-title":"A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.ejim.2022.04.020_bib0031","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"issue":"21","key":"10.1016\/j.ejim.2022.04.020_bib0032","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.ejim.2022.04.020_bib0033","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2022.04.020_bib0034","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/JAHA.115.002839","article-title":"High-sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in fabry disease","volume":"5","author":"Seydelmann","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"10.1016\/j.ejim.2022.04.020_bib0035","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ejim.2022.04.020_bib0036","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0735-1097(21)01891-X","article-title":"Long-term safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy: interim Results of the Mava-Long Term Extension (Lte) study","volume":"77","author":"Rader","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2022.04.020_bib0037","doi-asserted-by":"crossref","first-page":"596a","DOI":"10.1016\/j.bpj.2019.11.3225","article-title":"Characterization of the cardiac myosin inhibitor CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy","volume":"118","author":"Hartman","year":"2020","journal-title":"Biophys J"},{"issue":"5","key":"10.1016\/j.ejim.2022.04.020_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10050951","article-title":"Emerging medical treatment for hypertrophic cardiomyopathy","volume":"10","author":"Argir\u00f2","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2022.04.020_bib0039","article-title":"Cytokinetics announces positive topline results from cohort 3 of REDWOOD-HCM","author":"Siegall","year":"2022","journal-title":"Cytokinetics"},{"key":"10.1016\/j.ejim.2022.04.020_bib0040","article-title":"Cytokinetics announces start of open-label extension study for patients completing REDWOOD-HCM","author":"Weiser","year":"2022","journal-title":"Cytokinetics"},{"key":"10.1016\/j.ejim.2022.04.020_bib0041","article-title":"Cytokinetics reports third quarter 2021 financial results","author":"Siegall","year":"2022","journal-title":"Cytokinetics"},{"issue":"21","key":"10.1016\/j.ejim.2022.04.020_bib0042","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2022.04.020_bib0043","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/17482940802262376","article-title":"The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study","volume":"10","author":"Rossinen","year":"2008","journal-title":"Acute Card Care"},{"issue":"36","key":"10.1016\/j.ejim.2022.04.020_bib0044","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"10062","key":"10.1016\/j.ejim.2022.04.020_bib0045","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejim.2022.04.020_bib0046","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","article-title":"Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study","volume":"67","author":"Teerlink","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2022.04.020_bib0047","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF","volume":"8","author":"Teerlink","year":"2020","journal-title":"JACC Hear Fail"},{"issue":"6023","key":"10.1016\/j.ejim.2022.04.020_bib0048","first-page":"1439","volume":"331","author":"Malik","year":"2014","journal-title":"NIH Public Access"},{"key":"10.1016\/j.ejim.2022.04.020_bib0049","doi-asserted-by":"crossref","unstructured":"Shen Y.T., Malik F.I., Zhao X., et\u00a0al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Hear Fail. 2010;3(4):522\u20137. doi:10.1161\/CIRCHEARTFAILURE.109.930321.","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321"},{"issue":"2","key":"10.1016\/j.ejim.2022.04.020_bib0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2022.04.020_bib0051","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial","volume":"7","author":"Felker","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"25","key":"10.1016\/j.ejim.2022.04.020_bib0052","article-title":"Late-breaking science abstracts and featured science abstracts from the American Heart Association's Scientific sessions 2021 and late-breaking abstracts in resuscitation science from the Resuscitation Science Symposium 2021","volume":"144","author":"Specialty","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ejim.2022.04.020_bib0053","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/ejhf.1933","article-title":"Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial","volume":"22","author":"Voors","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.ejim.2022.04.020_bib0054","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522001637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522001637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:36:23Z","timestamp":1760607383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620522001637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":54,"alternative-id":["S0953620522001637"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2022.04.020","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2022.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}